BPC-157 / TB-500 Blend
$99.99
In stockThis research blend combines BPC-157 with TB-500 for preclinical investigation of complementary peptide pathways involving cellular migration, cytoskeletal regulation, vascular signaling, inflammation, and experimental tissue-repair models.
| SKU | RC-ST-BPC-TB500-10MGBL |
|---|---|
| Manufacturer | Strandix Peptides |
| Form | Lyophilized Powder |
| Strength | 10 mg / 10 mg |
| Size | 3 mL Vial |
| Reported Result | See matching batch report |
| Stock | In stock |
| Documentation Status | Client-supplied report available |
Product Description
BPC-157 is a synthetic peptide consisting of 15 amino acids. Laboratory research has examined its effects on tendon fibroblasts—the cells that help maintain and repair tendon tissue. Experiments have reported increased cell migration, tendon-cell outgrowth, and improved cell survival under stress, alongside activation of signaling pathways involved in cellular attachment and movement. These findings come from laboratory models rather than controlled human injury-recovery trials.
TB-500 is a name used for products related to thymosin beta-4, a peptide involved in cellular movement and tissue-repair biology. FDA identifies TB-500 as the seven-amino-acid thymosin beta-4 fragment LKKTETQ. This distinction matters: studies using full-length thymosin beta-4 cannot automatically establish the effects of the fragment or a commercial TB-500 product.
What research has shown:
Connective-tissue activity: BPC-157 has demonstrated effects on tendon-cell migration and survival in laboratory experiments.
Wound-repair findings: Animal research involving thymosin beta-4 and a synthetic peptide containing its actin-binding region has investigated wound closure and tissue repair. These findings do not demonstrate that a BPC-157/TB-500 blend heals human injuries.
Storage and handling: Store unopened lyophilized blend according to the manufacturer label and COA, protected from heat, light, and moisture. Avoid repeated temperature cycling. Do not assume that storage or reconstituted stability data for either individual component applies to the blend without product-specific validation.
Third-party testing status.
| Batch / Lot | Reported Result | Tested | Partner | Status | Document |
|---|---|---|---|---|---|
| BB10/2026-04-15 | Identity and amount only; purity not reported | Apr 30, 2026 | Janoshik | Identity / amount report; no purity | View COA |
.png)